In
vitro and
mouse studies suggest DCs could be useful for delivering Prograf
to treat autoimmune diseases. In cell culture, DCs treated with Prograf
sequestered and slowly released the drug over at least 72 hours. In a mouse
model of collagen-induced arthritis, transplantation of DCs previously
treated ex vivo with Prograf led to decreased arthritis severity
compared with transplantation of untreated cells. Next steps include further
defining potential autoantigens and more thorough safety testing. Astellas
Pharma Inc. markets Prograf tacrolimus for various
transplant and autoimmune indications.

Access this BioCentury Innovations article Distillery article for your individual use via a permanent link that allows you to read or print the article: $18.
The article link will be posted on the purchase transaction web page, and also emailed to you with your purchase confirmation.

Purchase This Article for Limited One-Time Distribution and Posting to Your Website :

Receive a formatted PDF reprint of this article with rights for limited one-time redistribution and posting to your website: $750. Please allow 24-48 hours for delivery.

Purchase Options

Purchase this article for individual use $18 USDPurchase this article for limited one-time distribution and website posting $750 USD